

2022 Interim Financial Report

Chassieu, October 3, 2022, 5.45 pm, AMOEBA (FR0011051598-ALMIB) - producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in the testing phase, announces today that it has published its Interim Financial Report for 2022.

AMOEBA's shareholders are informed that the interim financial report for the 2022 financial year (ending on December 31st, 2022), filed today with the Autorité des Marchés Financiers (AMF), can be found at the company website: <https://amoeba-nature.com/en/investor/financial-documents/>.

This report includes:

- Interim Activity Report
- Condensed Interim Financial Statements
- Certification of the person responsible for the interim financial report
- Statutory Auditors' Review Report on the interim financial information

About AMOEBA:

Founded in 2010, Amoéba is a French company, based in Chassieu (Lyon, France), specialised in the treatment of microbiological risk in natural resources. Over the last ten years, Amoéba has developed a triple scientific, industrial and commercial expertise around the amoeba *Willaertia magna* C2c Maky. This biological solution is an alternative to the chemical products widely used today. Amoéba is currently focusing on the biocontrol market for plant protection, estimated at €1.6 billion (1), as well as on the US market for industrial water treatment in closed circuits. In the long term, the Company plans to develop new applications such as the treatment of chronic wounds, valued at €751 million (2) in the United States. The commercialisation of crop protection, biocides and healthcare products is subject to local regulatory approvals. The company is currently testing the biocontrol application for plant protection and does not market any products.

Amoéba is listed on Euronext Growth. The Company is a member of the BPI Excellence network and is eligible for the PEA-PME scheme. More information on www.amoeba-nature.com.

1. *marketsandmarkets.com*, "Wound Care Market by Product, Wound Type, End User - Global Forecast to 2021," 2016.

2. Amoéba data

Contacts:

Amoéba

Valérie FILIATRE
Directeur Général Adjoint
+33 4 26 69 16 00
v.filiatre@amoeba-nature.com

Calyptus

Relations investisseurs & Presse
Nicolas HELIN/ Mathieu CALLEUX
+33 1 53 65 37 90 /91
amoeba@calyptus.net

Disclaimer

This press release contains certain forward-looking statements concerning AMOEBA which are based on its own assumptions and hypothesis and on information that are available to us. However, AMOEBA gives no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the Universal Registration Document of AMOEBA filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 12, 2022 under number D22-0282 (a copy of which is available on www.amoeba-nature.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or not currently considered material by AMOEBA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of AMOEBA to be materially different from such forward-looking statements.